XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
|
Citation:
|
XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
|
XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
|
Citation:
|
XU Kai-lin, ZHU Feng, WANG Jing-hua. A Promising Application Prospect, but It Still Has a Long Way to Go: Review on the Study of the Bispecific Antibody Flotetuzumab Targeting CD3 and CD123 in Relapsed/Refractory AML[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 95-97. DOI: 10.12019/j.issn.1671-5144.2022.02.006
|
DownLoad: